EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy

被引：7825

作者：

Paez, JG

Jänne, PA

Lee, JC

Tracy, S

Greulich, H

Gabriel, S

Herman, P

Kaye, FJ

Lindeman, N

Boggon, TJ

Naoki, K

Sasaki, H

Fujii, Y

Eck, MJ

Sellers, WR ^{[1
]}

Johnson, BE

Meyerson, M

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA

[3] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA

[4] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA

[5] Harvard Univ, Sch Med, Dept Biol Chem, Boston, MA 02115 USA

[6] Harvard Univ, Sch Med, Dept Mol Pharmacol, Boston, MA 02115 USA

[7] MIT & Harvard, Broad Inst, Cambridge, MA 02142 USA

[8] Natl Naval Med Res Inst, Genet Branch, NCI, Bethesda, MD 20889 USA

[9] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA

[10] Nagoya City Univ, Sch Med, Dept Surg 2, Nagoya, Aichi 4678601, Japan

来源：

SCIENCE | 2004年 / 304卷 / 5676期

关键词：

D O I：

10.1126/science.1099314

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Receptor tyrosine kinase genes were sequenced in non - small cell lung cancer (NSCLC) and matched normal tissue. Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States. Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan. EGFR mutations were found in additional lung cancer samples from U. S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines. These results suggest that EGFR mutations may predict sensitivity to gefitinib.

引用

页码：1497 / 1500

页数：4

共 26 条

[1]

[Anonymous], 2003, Lung Cancer

[2] Mutational analysis of the tyrosine kinome in colorectal cancers [J].

Bardelli, A ;

Parsons, DW ;

Silliman, N ;

Ptak, J ;

Szabo, S ;

Saha, S ;

Markowitz, S ;

Willson, JKV ;

Parmigiani, G ;

Kinzler, KW ;

Vogelstein, B ;

Velculescu, VE .

SCIENCE, 2003, 300 (5621) :949-949

[3] Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results [J].

Breathnach, OS ;

Freidlin, B ;

Conley, B ;

Green, MR ;

Johnson, DH ;

Gandara, DR ;

O'Connell, M ;

Shepherd, FA ;

Johnson, BE .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1734-1742

[4] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[5] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].

Demetri, GD ;

von Mehren, M ;

Blanke, CD ;

Van den Abbeele, AD ;

Eisenberg, B ;

Roberts, PJ ;

Heinrich, MC ;

Tuveson, DA ;

Singer, S ;

Janicek, M ;

Fletcher, JA ;

Silverman, SG ;

Silberman, SL ;

Capdeville, R ;

Kiese, B ;

Peng, B ;

Dimitrijevic, S ;

Druker, BJ ;

Corless, C ;

Fletcher, CDM ;

Joensuu, H .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480

[6] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042

[7] Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of paclitaxel [J].

Fujishita, T ;

Loda, M ;

Turner, RE ;

Gentler, M ;

Kashii, T ;

Breathnach, OS ;

Johnson, BE .

ONCOLOGY, 2003, 64 (04) :399-406

[8] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[9] Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1 [J].

Giaccone, G ;

Herbst, RS ;

Manegold, C ;

Scagliotti, G ;

Rosell, R ;

Miller, V ;

Natale, RB ;

Schiller, JH ;

von Pawel, J ;

Pluzanska, A ;

Gatzemeier, M ;

Grous, J ;

Ochs, JS ;

Averbuch, SD ;

Wolf, MK ;

Rennie, P ;

Fandi, A ;

Johnson, DH .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :777-784

[10] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

← 1 2 3 →